Exagen, Inc.

How big is Exagen, Inc.?

As of Jun 18, Exagen, Inc. has a market capitalization of 168.94 million, with net sales of 56.72 million and a net profit of -15.51 million over the last four quarters. Shareholder's funds are 9.54 million, and total assets amount to 45.40 million.

As of Jun 18, Exagen, Inc. has a market capitalization of 168.94 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 56.72 million, while the sum of net profit for the same period is -15.51 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 9.54 million and total assets amounting to 45.40 million.

What does Exagen, Inc. do?

Exagen, Inc. is a life sciences company focused on diagnostic and prognostic testing for autoimmune conditions, with recent net sales of $15 million and a market cap of $168.94 million. As of March 2025, it reported a net profit of -$4 million.

Overview:<BR>Exagen, Inc. is a commercial-stage life sciences company operating in the Pharmaceuticals & Biotechnology industry, specializing in diagnostic and prognostic testing for autoimmune conditions.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 15 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 168.94 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 1.70 <BR>Return on Equity: -242.18% <BR>Price to Book: 26.38 <BR><BR>Contact Details:<BR>Address: 1261 Liberty Way Ste C, VISTA CA: 92081-8356 <BR>Tel: 1 760 5601501 <BR>Website: http://www.exagen.com

Should I buy, sell or hold Exagen, Inc.?

Who are in the management team of Exagen, Inc.?

As of March 2022, the management team of Exagen, Inc. includes Mr. Brian Birk (Independent Chairman), Mr. Fortunato Rocca (President and CEO), and several Independent Directors: Mr. Jeffrey Elliott, Ms. Wendy Johnson, Dr. Tina Nova, Dr. Ebetuel Pallares, and Dr. Bruce Robertson.

As of March 2022, the management team of Exagen, Inc. includes the following individuals:<BR><BR>- Mr. Brian Birk, who serves as the Independent Chairman of the Board.<BR>- Mr. Fortunato Rocca, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Jeffrey Elliott, who is an Independent Director.<BR>- Ms. Wendy Johnson, who is also an Independent Director.<BR>- Dr. Tina Nova, serving as an Independent Director.<BR>- Dr. Ebetuel Pallares, who is an Independent Director.<BR>- Dr. Bruce Robertson, who is another Independent Director. <BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance of the company.

Is Exagen, Inc. technically bullish or bearish?

As of September 11, 2025, Exagen, Inc. shows a bullish technical trend despite mixed signals from the RSI and KST, having outperformed the S&P 500 with a year-to-date return of 135.37% compared to 12.22%.

As of 11 September 2025, the technical trend for Exagen, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, while the daily moving averages also indicate a bullish stance. However, the monthly RSI is bearish, and the KST shows a mildly bearish signal on the weekly timeframe. The Bollinger Bands are mildly bullish on both weekly and monthly charts. Overall, the technical stance is bullish but with some mixed signals, particularly from the RSI and KST.<BR><BR>In terms of performance, Exagen has significantly outperformed the S&P 500 year-to-date with a return of 135.37% compared to the S&P 500's 12.22%, and over the past year, it has returned 239.79% against the S&P 500's 17.14%.